Condyloma Acuminatum or genital warts are caused by the human papillomavirus (HPV) infection. As many as 40 strains of HPV are known to affect the anogenital area, with strains 6 and 11 usually causing Condyloma Acuminatum aka venereal warts. HPV spreads from sexual intercourse and age, while lifestyle also plays an important role in the development of genital warts. The condition can recur after topical treatment. Hence, it is essential to educate patients about treatment options, why they should have a follow-up appointment, and safe sex practices.
What are the Treatments of Condyloma Acuminatum?
Condyloma Acuminatum treatment or venereal wart treatment depends on several factors, including lesion type, location, and patient preference. Treatment options include:
- topical therapies Podophyllotoxin, Imiquimod, and Sinecatechins),
- in-clinic treatments (cryotherapy and TCA),
- and surgical excision.
In the case of topical treatments, multiple applications are required for weeks to a few months, with the application of Imiquimod showing lower recurrence rates. In-clinic options include cryotherapy and TCA, which are cost-effective, non-invasive, and suitable treatment options in case of lesions. Surgical excision, including electrosurgery and laser therapy, is meant for severe cases and has 100% clearance rates.
Another significant emerging treatment for genital warts is the application of 5-aminolevulinic acid (ALA) with photodynamic therapy. It shows more effective results in efficacy and lower recurrence rates than traditional methods such as CO2 laser treatment. Podophyllotoxin cream is an application method for treating fleshy papules or skin lesions.
Treatment initiation depends on lesion persistence, symptoms, and cosmetic concerns. Children and young, healthy adults may not require immediate treatment, as lesions can resolve spontaneously. Patients should seek treatment if lesions persist beyond two years, are symptomatic, or for cosmetic reasons.
Treatment options for Condyloma Acuminatum range from topical and in-clinic therapies to surgical excision, with ALA-based photodynamic therapy as a promising alternative. Individualised treatment decisions consider lesion characteristics and patient preferences.